Reskuin
Categorie
Reskuin Les marques, Reskuin Analogs
Reskuin Les marques melange
Reskuin Formule chimique
C36H42F2N6O9
Reskuin RX lien
http://www.rxlist.com/cgi/generic2/quixin.htm
Reskuin FDA fiche
Reskuin msds (fiche de securite des materiaux)
Reskuin Synthese de reference
Mitscher, Lester A. et al;. J. Med;. 30, 12, 2283-2286 (1987)
Reskuin Poids moleculaire
740.751 g/mol
Reskuin Point de fusion
No information avaliable
Reskuin H2O Solubilite
Insolubles
Reskuin Etat
Solid
Reskuin LogP
1.268
Reskuin Formes pharmaceutiques
Tablet; liquide; Solution
Reskuin Indication
Pour le traitement de la conjonctivite bactérienne causée par des souches sensibles des micro-organismes suivants: l'espèce Corynebacterium, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, , Streptococcus (Groupes C / F / G), le groupe viridans streptocoques, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Reskuin Pharmacologie
La lévofloxacine, un anti-infectieux des fluoroquinolones, est optiquement actif L-isomère de l'ofloxacine. La lévofloxacine est utilisé pour traiter la conjonctivite bactérienne, sinusite, bronchite chronique, pneumonie d'origine communautaire et la pneumonie provoquée par la pénicilline des souches résistantes de Streptococcus pneumoniae, les infections structure de la peau et la peau, des infections urinaires compliquées et pyélonéphrite aiguë.
Reskuin Absorption
L'absorption de l'ofloxacine après doses uniques ou multiples de 200 à 400 mg est prévisible, et la quantité de médicament absorbée augmente proportionnellement avec la dose.
Reskuin Toxicite
Les effets secondaires incluent la désorientation, étourdissements, somnolence, bouffées de chaleur et de froid, nausées, troubles d'élocution, de l'enflure et un engourdissement dans le visage
Reskuin Information pour les patients
PATIENT INFORMATION
While taking ofloxacin patient should be advised to:
� to drink fluids liberally;
� that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
� that ofloxacin can be taken without regard to meals;
� that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
� to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
� that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
� to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;
� that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
� that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
While taking ofloxacin patient should be advised to:
� to drink fluids liberally;
� that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
� that ofloxacin can be taken without regard to meals;
� that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
� to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
� that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
� to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;
� that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
� that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
Reskuin Organismes affectes
Bactéries entériques et d'autres eubactéries
